Amarantus Biosci Inc (AMBS) 0.1220 $AMBS
Amarantus Appoints Iain Ross to Board of Directors
GlobeNewswire - Fri Aug 29, 6:56AM CDT
Amarantus Bioscience Holdings, Inc. (OTCQB:AMBS), a biotechnology company focused on the development of diagnostic and therapeutic interventions for Alzheimer's disease, Parkinson's disease and orphan ophthalmological disorders, today announced the appointment of Mr. Iain Ross to the Company's Board of Directors, Mr. Ross brings over 30 years of biopharmaceutical industry experience to Amarantus across executive management, investment and directorship roles.
Amarantus Reports Second Quarter 2014 Financial Results, Announces Business Update Call
GlobeNewswire - Wed Aug 27, 8:00AM CDT
Amarantus Bioscience Holdings, Inc. (OTCQB:AMBS), a biotechnology company focused on the development of diagnostic and therapeutic interventions for Alzheimer's disease, Parkinson's disease and orphan ophthalmological disorders, reported financial results for the second quarter ended June 30, 2014 and announced a business update call on September 2, 2014. At August 27, 2014, the Company had cash and cash equivalents totaling approximately $2.4 million.
Amarantus to Present at Upcoming Investor Conferences
GlobeNewswire - Tue Aug 19, 7:41AM CDT
Amarantus Bioscience Holdings, Inc. (OTCQB:AMBS), a biotechnology company focused on the discovery and development of novel diagnostics and therapeutics related to endoplasmic reticulum stress, cell cycle dysregulation, neurodegeneration and apoptosis, today announced that Gerald Commissiong, President and CEO, is scheduled to present to investors at the 16th Annual Rodman & Renshaw Healthcare Conference to be held September 8-10, 2014 at the New York Palace Hotel in New York City. The presentation is scheduled for Tuesday, September 9th at 2:30 PM ET and will be web cast live, please visit the Company's IR Events section to participate. Additional information about the conference can be found at http://www.rodm.com/.
Amarantus announces exercise of option to license intellectual property from University of Miami Bascom Palmer Eye Institute for retinal disorders
M2 - Mon Aug 18, 6:39AM CDT
Biotechnology company Amarantus Bioscience Holdings (Other OTC:AMBS) reported on Friday that it has exercised its exclusive perpetual option to license intellectual property related to MANF's utility in treating retinal disorders from the University of Miami's Bascom Palmer Eye Institute.
Amarantus Exercises Option to License Intellectual Property From University of Miami Bascom Palmer Eye Institute for Use of MANF in Retinal Disorders
GlobeNewswire - Fri Aug 15, 7:10AM CDT
Amarantus Bioscience Holdings, Inc. (OTCQB:AMBS), a biotechnology company focused on the discovery and development of novel diagnostics and therapeutics related to endoplasmic reticulum stress, cell cycle dysregulation, neurodegeneration and apoptosis, announced that it exercised its exclusive option to license intellectual property related to MANF's utility in treating retinal disorders from the University of Miami's Bascom Palmer Eye Institute, and has entered into an exclusive license for said intellectual property. Under the terms of the agreement, the Company has been granted a perpetual, exclusive worldwide license to intellectual property, covering the use of MANF for the treatment of retinal disorders, including Retinitis pigmentosa.
Amarantus BioScience Holdings, Inc. "Preparing Amarantus for the Up-list in 2H-14: Capital Markets Strategy"
ACCESSWIRE - Mon Aug 11, 7:03AM CDT
New York, NY / ACCESSWIRE / August 11, 2014 / Amarantus BioScience Holdings, Inc. (OTCQB: AMBS) today published a new blog post on The Chairman's Blog, co-written by the Company's CEO, Mr. Gerald Commissiong and Chief Financial Officer, Mr. Robert Farrell, JD. TheChairmansBlog.com is an exclusive online media publication that enables key executive officers a unique platform to share insights about their company and industry trends.
Amarantus Enters Into Research Collaboration With the Buck Institute for Research on Aging for MANF
GlobeNewswire - Mon Aug 11, 7:00AM CDT
Amarantus Bioscience Holdings, Inc. (OTCQB:AMBS), a biotechnology company focused on the discovery and development of novel diagnostics and therapeutics related to endoplasmic reticulum stress, cell cycle dysregulation, neurodegeneration and apoptosis, announced it has entered into a Research Collaboration with theBuck Institute for Research on Aging for the development of Mesencephalic-Astrocyte-derived Neurotrophic Factor (MANF) in undisclosed therapeutic indications. MANF is a targeted therapeutic which addresses the underlying programmed cell death (apoptosis) associated with a wide range of devastating human disorders including orphan indications such as Retinitis Pigmentosa.
OTC Trading Stock News: Amarantus Biosciences Holdings, Inc. Virtus Oil and Gas Corp, Cannabis Sativa, Inc. Creative Edge Nutrition, Inc. DNA Brands, Inc.
PR Newswire Europe - Tue Aug 05, 7:03AM CDT
LONDON, August 5, 2014 /PRNewswire/ --
Amarantus BioScience Holdings, Inc. - "#C4CT Wrap-up and the Decision to Present Interim LP-002 Data"
ACCESSWIRE - Mon Aug 04, 3:26PM CDT
New York, NY / August 4, 2014 / Amarantus BioScience Holdings, Inc. (OTCQB: AMBS) today published a new blog post on The Chairman's Blog, written by the Company's CEO, Mr. Gerald Commissiong. TheChairmansBlog.com is an exclusive online media publication that enables key executive officers a unique platform to share insights about their company and industry trends.
#C4CT Summit Explored Emerging Theories on Traumatic Brain Injury, Chronic Traumatic Encephalopathy and Possible Links to Alzheimer's Disease
GlobeNewswire - Mon Aug 04, 7:04AM CDT
Brewer Sports International (BSI), a multi-faceted global advisory firm, andAmarantus BioScience Holdings, Inc. (OTCQB:AMBS), a biotechnology company focused on the discovery and development of novel diagnostics and therapeutics related to cell cycle dysregulation, endoplasmic reticulum stress, neurodegeneration and apoptosis, today reported that a cross-section of researchers, clinicians, policy-makers, patient groups and athletes presented at the 3 Alzheimer's focused #C4CT (Coalition for Concussion Treatment) Concussion Awareness Summit, powered by MDM Worldwide on Thursday, July 31, 2014 at the United Nations in New York City, NY.
Cerora, Inc. Announces Second Close in Seed Round of Financing
ACCESSWIRE - Fri Aug 01, 10:15AM CDT
Supports Proprietary 'Near the Field' Objective Concussion Evaluation Technology
Amarantus Announces Positive Top-Line Interim Clinical Data for Alzheimer's Blood Diagnostic LymPro Test(R)
GlobeNewswire - Fri Aug 01, 8:25AM CDT
Amarantus Bioscience Holdings, Inc. (OTCQB:AMBS), a biotechnology company focused on the discovery and development of novel diagnostics and therapeutics related to endoplasmic reticulum stress, cell cycle dysregulation, neurodegeneration and apoptosis, today announced positive interim clinical performance data for the Company's proprietary cell cycle dysregulation diagnostic blood assay LymPro Test(R), currently under development for Alzheimer's disease diagnosis. In an interim analysis of 44 subjects (34 healthy controls and 10 Alzheimer's patients) from LP-002, a projected 72 patient clinical performance study, the Company announced it achieved replication of the two earlier peer reviewed publications, the primary objective of the study.
Amarantus Acquires Exclusive Option to License Alzheimer's Therapeutic IP of Dr. Thomas Arendt From University of Leipzig
GlobeNewswire - Fri Aug 01, 7:41AM CDT
Amarantus Bioscience Holdings, Inc. (OTCQB:AMBS), a biotechnology company focused on the discovery and development of novel diagnostics and therapeutics related to endoplasmic reticulum stress, cell cycle dysregulation, neurodegeneration and apoptosis, today announced that it has acquired an exclusive option to license the intellectual property surrounding the therapeutic concepts of Dr. Thomas Arendt from the University of Leipzig that were presented at the 3 Alzheimer's focused Coalition for Concussion Treatment Summit. Under the terms of the agreement, the Company and the University of Leipzig will have 12 months to negotiate a definitive license agreement, and the Company will work with Dr. Arendt to establish a Sponsored Research Agreement to outline the advancement of the therapeutic strategies into human clinical development.
The 3rd Alzheimer's-Focused #C4CT Concussion Summit Convenes Today at the United Nations
GlobeNewswire - Thu Jul 31, 9:48AM CDT
Brewer Sports International (BSI), a multi-faceted global sports advisory firm, and Amarantus BioScience Holdings, Inc. (OTCQB:AMBS), a biotechnology company focused on the discovery and development of novel diagnostics and therapeutics related to cell cycle dysregulation, endoplasmic reticulum stress, neurodegeneration and apoptosis, will be hosting the 3 Alzheimer's-Focused #C4CT Summit powered by MDM Worldwide at the United Nations today.
Registration for the 3rd Alzheimer's-Focused #C4CT Summit Has Closed Due to Overwhelming Interest
GlobeNewswire - Wed Jul 30, 7:06AM CDT
Brewer Sports International (BSI), a multi-faceted global sports advisory firm, and Amarantus BioScience Holdings, Inc. (OTCQB:AMBS), a biotechnology company focused on the discovery and development of novel diagnostics and therapeutics related to cell cycle dysregulation, endoplasmic reticulum stress, neurodegeneration and apoptosis, today announced that due to overwhelming registration for the upcoming #C4CT Summit to be held at the United Nations on July 31, 2014, the Coalition for Concussion Treatment is reluctantly unable to accept any new registrants. This summit will be the largest to date with hundreds of confirmed guests including doctors and medical researchers specializing in the treatment of neurodegenerative diseases, policy makers, international ambassadors, athletes and victims of traumatic brain injury (TBI). The summit will cover Alzheimer's disease and other neurodegenerative diseases and the emerging link between traumatic brain injury and neurological conditions.
Amarantus Amends LymPro LP-002 Clinical Protocol to Report Interim Data at #C4CT Presentation
GlobeNewswire - Wed Jul 30, 7:00AM CDT
Amarantus Bioscience Holdings, Inc. (OTCQB:AMBS), a biotechnology company focused on the discovery and development of novel diagnostics and therapeutics related to endoplasmic reticulum stress, cell cycle dysregulation, neurodegeneration and apoptosis, today announced that it has amended the clinical protocol for its LP-002 Alzheimer's disease bridging diagnostic study of LymPro in order to perform an interim analysis of 44 subjects recruited from a single clinical site, from an originally planned 72 subjects across 4 clinical sites. The Company intends to report full results upon completion of study enrollment from the three additional clinical sites in the 3 quarter. The Company remains on track to achieve its strategic objectives for LymPro in the 2 half of 2014.
Cognitive Impairment Associated With Schizophrenia (CIAS) - Pipeline Review, H1 2014
M2 - Wed Jul 30, 3:04AM CDT
Research and Markets (http://www.researchandmarkets.com/research/djdwhf/cognitive) has announced the addition of the "Cognitive Impairment Associated With Schizophrenia (CIAS) - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Cognitive Impairment Associated With Schizophrenia (CIAS), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Cognitive Impairment Associated With Schizophrenia (CIAS) and special features on late-stage and discontinued projects. Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Cognitive Impairment Associated With Schizophrenia (CIAS) - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Cognitive Impairment Associated With Schizophrenia (CIAS) pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope Companies Mentioned: - Eli Lilly and Company - Merck & Co., Inc. - Takeda Pharmaceutical Company Limited - Avineuro Pharmaceuticals, Inc. - Novartis AG - FORUM Pharmaceuticals Inc. - H. Lundbeck A/S - Pfizer Inc. - Suven Life Sciences Ltd. - Mithridion, Inc. - CoMentis, Inc. - Upsher-Smith Laboratories, Inc. - Siena Biotech S.p.A. - Dart NeuroScience LLC - Intra-Cellular Therapies, Inc. - Amarantus Bioscience Holdings, Inc. - Mnemosyne Pharmaceuticals, Inc. - SK Biopharmaceuticals Co., Ltd. - AbbVie Inc. - Saniona AB For more information visit http://www.researchandmarkets.com/research/djdwhf/cognitive
Sidney Rice and Ben Utecht Talk to NFL Network's Andrea Kremer and ESPN's Andrew Brandt at Upcoming #C4CT Concussion Awareness Summit at the United Nations
GlobeNewswire - Mon Jul 28, 2:16PM CDT
Brewer Sports International (BSI), a multi-faceted global sports advisory firm, and Amarantus BioScience Holdings, Inc. (OTCQB:AMBS), a biotechnology company focused on the discovery and development of novel diagnostics and therapeutics related to cell cycle dysregulation, endoplasmic reticulum stress, neurodegeneration and apoptosis, are pleased to provide an update surrounding the 3 Alzheimer's focused #C4CT (Coalition for Concussion Treatment) Concussion Awareness Summit, powered by MDM Worldwide on Thursday, July 31, 2014 at the United Nations in New York City, NY.
Amarantus Appoints Iain Ross to Board of Directors
GlobeNewswire - Fri Aug 29, 6:56AM CDT
Amarantus Bioscience Holdings, Inc. (OTCQB:AMBS), a biotechnology company focused on the development of diagnostic and therapeutic interventions for Alzheimer's disease, Parkinson's disease and orphan ophthalmological disorders, today announced the appointment of Mr. Iain Ross to the Company's Board of Directors, Mr. Ross brings over 30 years of biopharmaceutical industry experience to Amarantus across executive management, investment and directorship roles.
Amarantus Reports Second Quarter 2014 Financial Results, Announces Business Update Call
GlobeNewswire - Wed Aug 27, 8:00AM CDT
Amarantus Bioscience Holdings, Inc. (OTCQB:AMBS), a biotechnology company focused on the development of diagnostic and therapeutic interventions for Alzheimer's disease, Parkinson's disease and orphan ophthalmological disorders, reported financial results for the second quarter ended June 30, 2014 and announced a business update call on September 2, 2014. At August 27, 2014, the Company had cash and cash equivalents totaling approximately $2.4 million.
Amarantus to Present at Upcoming Investor Conferences
GlobeNewswire - Tue Aug 19, 7:41AM CDT
Amarantus Bioscience Holdings, Inc. (OTCQB:AMBS), a biotechnology company focused on the discovery and development of novel diagnostics and therapeutics related to endoplasmic reticulum stress, cell cycle dysregulation, neurodegeneration and apoptosis, today announced that Gerald Commissiong, President and CEO, is scheduled to present to investors at the 16th Annual Rodman & Renshaw Healthcare Conference to be held September 8-10, 2014 at the New York Palace Hotel in New York City. The presentation is scheduled for Tuesday, September 9th at 2:30 PM ET and will be web cast live, please visit the Company's IR Events section to participate. Additional information about the conference can be found at http://www.rodm.com/.
Amarantus announces exercise of option to license intellectual property from University of Miami Bascom Palmer Eye Institute for retinal disorders
M2 - Mon Aug 18, 6:39AM CDT
Biotechnology company Amarantus Bioscience Holdings (Other OTC:AMBS) reported on Friday that it has exercised its exclusive perpetual option to license intellectual property related to MANF's utility in treating retinal disorders from the University of Miami's Bascom Palmer Eye Institute.
Amarantus Exercises Option to License Intellectual Property From University of Miami Bascom Palmer Eye Institute for Use of MANF in Retinal Disorders
GlobeNewswire - Fri Aug 15, 7:10AM CDT
Amarantus Bioscience Holdings, Inc. (OTCQB:AMBS), a biotechnology company focused on the discovery and development of novel diagnostics and therapeutics related to endoplasmic reticulum stress, cell cycle dysregulation, neurodegeneration and apoptosis, announced that it exercised its exclusive option to license intellectual property related to MANF's utility in treating retinal disorders from the University of Miami's Bascom Palmer Eye Institute, and has entered into an exclusive license for said intellectual property. Under the terms of the agreement, the Company has been granted a perpetual, exclusive worldwide license to intellectual property, covering the use of MANF for the treatment of retinal disorders, including Retinitis pigmentosa.
Amarantus BioScience Holdings, Inc. "Preparing Amarantus for the Up-list in 2H-14: Capital Markets Strategy"
ACCESSWIRE - Mon Aug 11, 7:03AM CDT
New York, NY / ACCESSWIRE / August 11, 2014 / Amarantus BioScience Holdings, Inc. (OTCQB: AMBS) today published a new blog post on The Chairman's Blog, co-written by the Company's CEO, Mr. Gerald Commissiong and Chief Financial Officer, Mr. Robert Farrell, JD. TheChairmansBlog.com is an exclusive online media publication that enables key executive officers a unique platform to share insights about their company and industry trends.
Amarantus Enters Into Research Collaboration With the Buck Institute for Research on Aging for MANF
GlobeNewswire - Mon Aug 11, 7:00AM CDT
Amarantus Bioscience Holdings, Inc. (OTCQB:AMBS), a biotechnology company focused on the discovery and development of novel diagnostics and therapeutics related to endoplasmic reticulum stress, cell cycle dysregulation, neurodegeneration and apoptosis, announced it has entered into a Research Collaboration with theBuck Institute for Research on Aging for the development of Mesencephalic-Astrocyte-derived Neurotrophic Factor (MANF) in undisclosed therapeutic indications. MANF is a targeted therapeutic which addresses the underlying programmed cell death (apoptosis) associated with a wide range of devastating human disorders including orphan indications such as Retinitis Pigmentosa.
OTC Trading Stock News: Amarantus Biosciences Holdings, Inc. Virtus Oil and Gas Corp, Cannabis Sativa, Inc. Creative Edge Nutrition, Inc. DNA Brands, Inc.
PR Newswire Europe - Tue Aug 05, 7:03AM CDT
LONDON, August 5, 2014 /PRNewswire/ --
Amarantus BioScience Holdings, Inc. - "#C4CT Wrap-up and the Decision to Present Interim LP-002 Data"
ACCESSWIRE - Mon Aug 04, 3:26PM CDT
New York, NY / August 4, 2014 / Amarantus BioScience Holdings, Inc. (OTCQB: AMBS) today published a new blog post on The Chairman's Blog, written by the Company's CEO, Mr. Gerald Commissiong. TheChairmansBlog.com is an exclusive online media publication that enables key executive officers a unique platform to share insights about their company and industry trends.
#C4CT Summit Explored Emerging Theories on Traumatic Brain Injury, Chronic Traumatic Encephalopathy and Possible Links to Alzheimer's Disease
GlobeNewswire - Mon Aug 04, 7:04AM CDT
Brewer Sports International (BSI), a multi-faceted global advisory firm, andAmarantus BioScience Holdings, Inc. (OTCQB:AMBS), a biotechnology company focused on the discovery and development of novel diagnostics and therapeutics related to cell cycle dysregulation, endoplasmic reticulum stress, neurodegeneration and apoptosis, today reported that a cross-section of researchers, clinicians, policy-makers, patient groups and athletes presented at the 3 Alzheimer's focused #C4CT (Coalition for Concussion Treatment) Concussion Awareness Summit, powered by MDM Worldwide on Thursday, July 31, 2014 at the United Nations in New York City, NY.
Cerora, Inc. Announces Second Close in Seed Round of Financing
ACCESSWIRE - Fri Aug 01, 10:15AM CDT
Supports Proprietary 'Near the Field' Objective Concussion Evaluation Technology
Amarantus Announces Positive Top-Line Interim Clinical Data for Alzheimer's Blood Diagnostic LymPro Test(R)
GlobeNewswire - Fri Aug 01, 8:25AM CDT
Amarantus Bioscience Holdings, Inc. (OTCQB:AMBS), a biotechnology company focused on the discovery and development of novel diagnostics and therapeutics related to endoplasmic reticulum stress, cell cycle dysregulation, neurodegeneration and apoptosis, today announced positive interim clinical performance data for the Company's proprietary cell cycle dysregulation diagnostic blood assay LymPro Test(R), currently under development for Alzheimer's disease diagnosis. In an interim analysis of 44 subjects (34 healthy controls and 10 Alzheimer's patients) from LP-002, a projected 72 patient clinical performance study, the Company announced it achieved replication of the two earlier peer reviewed publications, the primary objective of the study.
Amarantus Acquires Exclusive Option to License Alzheimer's Therapeutic IP of Dr. Thomas Arendt From University of Leipzig
GlobeNewswire - Fri Aug 01, 7:41AM CDT
Amarantus Bioscience Holdings, Inc. (OTCQB:AMBS), a biotechnology company focused on the discovery and development of novel diagnostics and therapeutics related to endoplasmic reticulum stress, cell cycle dysregulation, neurodegeneration and apoptosis, today announced that it has acquired an exclusive option to license the intellectual property surrounding the therapeutic concepts of Dr. Thomas Arendt from the University of Leipzig that were presented at the 3 Alzheimer's focused Coalition for Concussion Treatment Summit. Under the terms of the agreement, the Company and the University of Leipzig will have 12 months to negotiate a definitive license agreement, and the Company will work with Dr. Arendt to establish a Sponsored Research Agreement to outline the advancement of the therapeutic strategies into human clinical development.
The 3rd Alzheimer's-Focused #C4CT Concussion Summit Convenes Today at the United Nations
GlobeNewswire - Thu Jul 31, 9:48AM CDT
Brewer Sports International (BSI), a multi-faceted global sports advisory firm, and Amarantus BioScience Holdings, Inc. (OTCQB:AMBS), a biotechnology company focused on the discovery and development of novel diagnostics and therapeutics related to cell cycle dysregulation, endoplasmic reticulum stress, neurodegeneration and apoptosis, will be hosting the 3 Alzheimer's-Focused #C4CT Summit powered by MDM Worldwide at the United Nations today.
Registration for the 3rd Alzheimer's-Focused #C4CT Summit Has Closed Due to Overwhelming Interest
GlobeNewswire - Wed Jul 30, 7:06AM CDT
Brewer Sports International (BSI), a multi-faceted global sports advisory firm, and Amarantus BioScience Holdings, Inc. (OTCQB:AMBS), a biotechnology company focused on the discovery and development of novel diagnostics and therapeutics related to cell cycle dysregulation, endoplasmic reticulum stress, neurodegeneration and apoptosis, today announced that due to overwhelming registration for the upcoming #C4CT Summit to be held at the United Nations on July 31, 2014, the Coalition for Concussion Treatment is reluctantly unable to accept any new registrants. This summit will be the largest to date with hundreds of confirmed guests including doctors and medical researchers specializing in the treatment of neurodegenerative diseases, policy makers, international ambassadors, athletes and victims of traumatic brain injury (TBI). The summit will cover Alzheimer's disease and other neurodegenerative diseases and the emerging link between traumatic brain injury and neurological conditions.
Amarantus Amends LymPro LP-002 Clinical Protocol to Report Interim Data at #C4CT Presentation
GlobeNewswire - Wed Jul 30, 7:00AM CDT
Amarantus Bioscience Holdings, Inc. (OTCQB:AMBS), a biotechnology company focused on the discovery and development of novel diagnostics and therapeutics related to endoplasmic reticulum stress, cell cycle dysregulation, neurodegeneration and apoptosis, today announced that it has amended the clinical protocol for its LP-002 Alzheimer's disease bridging diagnostic study of LymPro in order to perform an interim analysis of 44 subjects recruited from a single clinical site, from an originally planned 72 subjects across 4 clinical sites. The Company intends to report full results upon completion of study enrollment from the three additional clinical sites in the 3 quarter. The Company remains on track to achieve its strategic objectives for LymPro in the 2 half of 2014.
Cognitive Impairment Associated With Schizophrenia (CIAS) - Pipeline Review, H1 2014
M2 - Wed Jul 30, 3:04AM CDT
Research and Markets (http://www.researchandmarkets.com/research/djdwhf/cognitive) has announced the addition of the "Cognitive Impairment Associated With Schizophrenia (CIAS) - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Cognitive Impairment Associated With Schizophrenia (CIAS), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Cognitive Impairment Associated With Schizophrenia (CIAS) and special features on late-stage and discontinued projects. Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Cognitive Impairment Associated With Schizophrenia (CIAS) - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Cognitive Impairment Associated With Schizophrenia (CIAS) pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope Companies Mentioned: - Eli Lilly and Company - Merck & Co., Inc. - Takeda Pharmaceutical Company Limited - Avineuro Pharmaceuticals, Inc. - Novartis AG - FORUM Pharmaceuticals Inc. - H. Lundbeck A/S - Pfizer Inc. - Suven Life Sciences Ltd. - Mithridion, Inc. - CoMentis, Inc. - Upsher-Smith Laboratories, Inc. - Siena Biotech S.p.A. - Dart NeuroScience LLC - Intra-Cellular Therapies, Inc. - Amarantus Bioscience Holdings, Inc. - Mnemosyne Pharmaceuticals, Inc. - SK Biopharmaceuticals Co., Ltd. - AbbVie Inc. - Saniona AB For more information visit http://www.researchandmarkets.com/research/djdwhf/cognitive
Sidney Rice and Ben Utecht Talk to NFL Network's Andrea Kremer and ESPN's Andrew Brandt at Upcoming #C4CT Concussion Awareness Summit at the United Nations
GlobeNewswire - Mon Jul 28, 2:16PM CDT
Brewer Sports International (BSI), a multi-faceted global sports advisory firm, and Amarantus BioScience Holdings, Inc. (OTCQB:AMBS), a biotechnology company focused on the discovery and development of novel diagnostics and therapeutics related to cell cycle dysregulation, endoplasmic reticulum stress, neurodegeneration and apoptosis, are pleased to provide an update surrounding the 3 Alzheimer's focused #C4CT (Coalition for Concussion Treatment) Concussion Awareness Summit, powered by MDM Worldwide on Thursday, July 31, 2014 at the United Nations in New York City, NY.
